Preeti Jaggi

Preeti Jaggi


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Pediatrics
Verified
Journal Article
Closed access
PDF file
CRChristina Rostad
Christina Rostad
ACAnn Chahroudi
Ann Chahroudi
GMGrace Mantus
Grace Mantus
SLStacey A. Lapp
Stacey A. Lapp
MTMehgan Teherani
Mehgan Teherani
PJPreeti Jaggi
Preeti Jaggi
OBJECTIVES: We aimed to measure severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological responses in children hospitalized with multisystem inflammatory syndrome in children (MIS-C) compared with those with coronavirus disease 2019 (COVID-19), those with Kawasaki disease (KD), and hospitalized pediatric controls. METHODS: From March 17, 2020, to May 26, 2020, we prospectively identified hospitalized children with MIS-C (n = 10), symptomatic COVID-19 (n = 10), and KD (n = 5) and hospitalized controls (n = 4) at Children’s Healthcare of Atlanta. With institutional review board approval, we obtained prospective and residual blood samples from these children and measured SARS-CoV-2 spike receptor-binding domain (RBD) immunoglobulin M and immunoglobulin G (IgG), full-length spike IgG, and nucleocapsid protein antibodies using quantitative enzyme-linked immunosorbent assays and SARS-CoV-2 neutralizing antibodies using live-virus focus-reduction neutralization assays. We statistically compared the log-transformed antibody titers among groups and performed linear regression analyses. RESULTS: All children with MIS-C had high titers of SARS-CoV-2 RBD IgG antibodies, which correlated with full-length spike IgG antibodies (R2 = 0.956; P < .001), nucleocapsid protein antibodies (R2 = 0.846; P < .001), and neutralizing antibodies (R2 = 0.667; P < .001). Children with MIS-C had significantly higher SARS-CoV-2 RBD IgG antibody titers (geometric mean titer 6800; 95% confidence interval 3495–13 231) than children with COVID-19 (geometric mean titer 626; 95% confidence interval 251–1563; P < .001), children with KD (geometric mean titer 124; 95% confidence interval 91–170; P < .001), and hospitalized controls (geometric mean titer 85; P < .001). All children with MIS-C also had detectable RBD immunoglobulin M antibodies, indicating recent SARS-CoV-2 infection. RBD IgG titers correlated with the erythrocyte sedimentation rate (R2 = 0.512; P < .046) and with hospital (R2 = 0.548; P = .014) and ICU lengths of stay (R2 = 0.590; P = .010). CONCLUSIONS: Quantitative SARS-CoV-2 serology may have a role in establishing the diagnosis of MIS-C, distinguishing it from similar clinical entities, and stratifying risk for adverse outcomes.

29 May 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PJPreeti Jaggi
Preeti Jaggi
AMAsuncion Mejias
Asuncion Mejias
ZXZhaohui Xu
Zhaohui Xu
HYHan Yin
Han Yin
MMMelissa Moore-Clingenpeel
Melissa Moore-Clingenpeel
OROctavio Ramilo
Octavio Ramilo
Early identification of children with Kawasaki Disease (KD) is key for timely initiation of intravenous immunoglobulin (IVIG) therapy. However, the diagnosis of the disease remains challenging, especially in children with an incomplete presentation (inKD). Moreover, we currently lack objective tools for identification of non-response (NR) to IVIG. Children with KD were enrolled and samples obtained before IVIG treatment and sequentially at 24 h and 4–6 weeks post-IVIG in a subset of patients. We also enrolled children with other febrile illnesses [adenovirus (AdV); group A streptococcus (GAS)] and healthy controls (HC) for comparative analyses. Blood transcriptional profiles were analyzed to define: a) the cKD and inKD biosignature, b) compare the KD signature with other febrile illnesses and, c) identify biomarkers predictive of clinical outcomes. We identified a cKD biosignature (n = 39; HC, n = 16) that was validated in two additional cohorts of children with cKD (n = 37; HC, n = 20) and inKD (n = 13; HC, n = 8) and was characterized by overexpression of inflammation, platelets, apoptosis and neutrophil genes, and underexpression of T and NK cell genes. Classifier genes discriminated KD from adenovirus with higher sensitivity and specificity (92% and 100%, respectively) than for GAS (75% and 87%, respectively). We identified a genomic score (MDTH) that was higher at baseline in IVIG-NR [median 12,290 vs. 5,572 in responders, p = 0.009] and independently predicted IVIG-NR. A reproducible biosignature from KD patients was identified, and was similar in children with cKD and inKD. A genomic score allowed early identification of children at higher risk for non-response to IVIG.

11 August 2020 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Open access
PDF file
MTMehgan F Teherani
Mehgan F Teherani
CKCarol Kao
Carol Kao
ACAndres Camacho-Gonzalez
Andres Camacho-Gonzalez
SBSamridhi Banskota
Samridhi Banskota
ASAndi L Shane
Andi L Shane
PJPreeti Jaggi
Preeti Jaggi
We investigated of illness among household members of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–infected children receiving medical care (n = 32). We identified 144 household contacts (HCs): 58 children and 86 adults. Forty-six percent of HCs developed symptoms consistent with coronavirus disease. Child-to-adult transmission was suspected in 7 cases.

21 September 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
MTMehgan Teherani
Mehgan Teherani
SBSamridhi Banskota
Samridhi Banskota
ACAndres Camacho-Gonzalez
Andres Camacho-Gonzalez
ASAlison G. C. Smith
Alison G. C. Smith
EAEvan Anderson
Evan Anderson
PJPreeti Jaggi
Preeti Jaggi
A paucity of data exists evaluating a guardian’s intent to vaccinate their child against COVID-19 in the United States. We administered 102 first (April–November 2020) and 45 second (December–January 2020–2021) surveys to guardians of children (<18 years) who had a laboratory-confirmed diagnosis of COVID-19 and assessed their intent to give a COVID-19 vaccine to their child, when one becomes available. The first and second surveys of the same cohort of guardians were conducted before and following the press releases detailing the adult Pfizer-BioNTech and Moderna Phase 3 results. Both surveys included an intent-to-vaccinate question using the subjective language of “if a safe and effective vaccine” became available, and a second question was added to second surveys using the objective language of “would prevent 19 of 20 people from getting disease”. When using subjective language, 24 of 45 (53%) guardians endorsed vaccine administration for their children in the first survey, which decreased to 21 (46%) in the second survey. When adding objective language, acceptance of vaccination increased to 31 (69%, p = 0.03). Common reasons for declining vaccination were concerns about adverse effects and/or vaccine safety. Providing additional facts on vaccine efficacy increased vaccine acceptance. Evidence-based strategies are needed to increase pediatric COVID-19 vaccine uptake.

9 January 2013 in Journal of the Pediatric Infectious Diseases Society
Verified
Journal Article
Open access
PDF file
EAEvan Anderson
Evan Anderson
PAPaul B. Ahn
Paul B. Ahn
RYRam Yogev
Ram Yogev
PJPreeti Jaggi
Preeti Jaggi
DSDeanna B. Shippee
Deanna B. Shippee
SSStanford T. Shulman
Stanford T. Shulman
We retrospectively reviewed 14 children with active blastomycosis. Pulmonary disease occurred in 86% of the cohort and extrapulmonary dissemination was noted in 46%. Urine blastomycosis or histoplasmosis antigens were positive in all tested patients. Acute kidney injury was common in patients who were treated with amphotericin. Mortality tended to be associated with a delay in diagnosis.

2 July 2018 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
PJPreeti Jaggi
Preeti Jaggi
LWLing Wang
Ling Wang
SGSean Gleeson
Sean Gleeson
MMMelissa Moore-Clingenpeel
Melissa Moore-Clingenpeel
JWJoshua Watson
Joshua Watson
ObjectiveWe sought to identify factors associated with long duration and/or non–first-line choice of treatment for pediatric skin and soft-tissue infections (SSTIs).DesignRetrospective cohort study.SettingAmbulatory encounter claims of Medicaid-insured children lacking chronic medical conditions treated for SSTI and/or animal bite injury in Ohio in 2014.MethodsFor all diagnoses, long treatment duration was defined as treatment >7 days. Non–first-line choice of treatment for SSTI included treatment with 2 antimicrobials dispensed on the same calendar day or any treatment not listed in the Infectious Diseases Society of America guidelines. The adjusted odds of (1) long treatment duration and (2) non–first-line choice of treatment were calculated for patient age, prescriber type, and patient county of residence characteristics (ie, rural vs metropolitan area and poverty rate).ResultsOf 10,310 encounters with complete data available, long treatment duration was prescribed in 7,968 (77.3%). The most common duration of treatment prescribed was 10 days. A non–first-line choice was prescribed in 1,030 encounters (10%). Dispensation of 2 antimicrobials on the same calendar day was the most common reason for the non–first-line choice, and of these, trimethoprim-sulfamethoxazole plus a first-generation cephalosporin was the most common regimen. Compared to pediatricians, the adjusted odds ratio of long treatment duration was significantly lower for all other primary care specialties. Conversely, nonpediatricians were more likely to prescribe a non–first-line treatment choice. Patient residence in a high-poverty county increased the odds of both long duration and non–first-line choice of treatment.ConclusionsHealthcare claims may be utilized to measure opportunities for first-line choice and/or shorter duration of treatment for SSTI.